Adapting Biopharma to AI: A 2024 Update with Greg Meyers
About this episode
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.
This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI. Now, they revisit the conversation to see what’s changed and what hasn’t.
Together, they chat through tech as a competitive differentiator for large companies, generative AI for drug development, and what Greg and BMS look for in potential partners. They also highlight the importance of being agile and adaptable while navigating the changing landscape of biotech, providing valuable insights for founders.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Raising Health publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Raising Health
Moderna CEO Stéphane Bancel on the Next Era of mRNA
Raising Health
Clinical AI Comes of Age | Suchi Saria on the Future of Healthcare
Raising Health
AI, Healthcare, and 700 Million Patients | Nicolas Abad, Telepatía
Raising Health
Healthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
Raising Health